Athenex Past Earnings Performance
Past criteria checks 0/6
Athenex's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 11.2% per year.
Key information
-7.6%
Earnings growth rate
9.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 11.2% |
| Return on equity | n/a |
| Net Margin | -95.3% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Athenex prices $30M in stock and warrants offering
Aug 11Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal
Aug 05Athenex GAAP EPS, revenue misses estimates
Jul 28Athenex to sell its China API business for $19M
Jul 11Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.
Aug 31Athenex EPS beats by $0.13, beats on revenue
May 06Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?
Apr 04
Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?
Mar 09These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts
Mar 06Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?
Feb 19When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?
Jan 29
Revenue & Expenses Breakdown
How Athenex makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 103 | -98 | 49 | 52 |
| 30 Sep 22 | 123 | -178 | 70 | 56 |
| 30 Jun 22 | 121 | -192 | 71 | 65 |
| 31 Mar 22 | 109 | -198 | 67 | 71 |
| 31 Dec 21 | 95 | -158 | 57 | 78 |
| 30 Sep 21 | 113 | -132 | 75 | 78 |
| 30 Jun 21 | 117 | -135 | 83 | 79 |
| 31 Mar 21 | 137 | -144 | 86 | 80 |
| 31 Dec 20 | 144 | -142 | 93 | 76 |
| 30 Sep 20 | 157 | -118 | 84 | 79 |
| 30 Jun 20 | 141 | -116 | 78 | 80 |
| 31 Mar 20 | 123 | -108 | 77 | 101 |
| 31 Dec 19 | 101 | -123 | 66 | 84 |
| 30 Sep 19 | 88 | -129 | 60 | 65 |
| 30 Jun 19 | 87 | -141 | 55 | 46 |
| 31 Mar 19 | 77 | -145 | 51 | 3 |
| 31 Dec 18 | 89 | -117 | 49 | 120 |
| 30 Sep 18 | 83 | -119 | 50 | 0 |
| 30 Jun 18 | 78 | -96 | 49 | 0 |
| 31 Mar 18 | 71 | -97 | 49 | 0 |
| 31 Dec 17 | 38 | -131 | 46 | 2 |
| 30 Sep 17 | 28 | -143 | 44 | 0 |
| 30 Jun 17 | 20 | -144 | 40 | 0 |
| 31 Mar 17 | 21 | -118 | 31 | 0 |
| 31 Dec 16 | 21 | -88 | 26 | 0 |
| 30 Sep 16 | 21 | -61 | 21 | 0 |
| 31 Dec 15 | 14 | -51 | 26 | 0 |
| 31 Dec 14 | 1 | -18 | 5 | 2 |
Quality Earnings: ATNX.Q is currently unprofitable.
Growing Profit Margin: ATNX.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATNX.Q is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare ATNX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATNX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: ATNX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.